1.354 makale bulundu

Five-Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease.

Gonzalez-Latapi P, Gochanour C, Choi SH, Cho H, Caspell-Garcia C, Coffey C, Brumm M, Lafontant DE, Xiao Y, Tropea T, Seibyl J, Tanner C, Venuto CS, Kieburtz K, Chahine LM, Poston KL, Siderowf A, Marek K, Simuni T, Parkinson's Progression Markers Initiative.

Ann Clin Transl Neurol · 2026-03-10

DOI: 10.1002/acn3.70323PMID: 41808287

M[Formula: see text]DGAT: Multi-view multi-scale dynamic graph attention network(GAT) based prediction of Parkinson's disease(PD) progression using whole-blood RNA sequencing data.

Wei Z, Zeqi X, Chenjun W, Qi D.

Sci Rep · 2026-03-02

DOI: 10.1038/s41598-026-40636-xPMID: 41771960

A deep clustering Gaussian process algorithm for motor progression prediction of Parkinson's disease.

Pan C, Tian Y, Zhou T, Chi S, Wu C, Ma L, Ren K, Feng T, Li J.

Comput Methods Programs Biomed · 2026-03-02

DOI: 10.1016/j.cmpb.2026.109305PMID: 41825292

Disruption of the white matter structural network and its association with clinical subtypes and disease progression in parkinson's disease.

Chen Z, He C, Zhang P, Cai X, Li X, Huang W, Zhan P, Cai M, Zhang Y.

Brain Imaging Behav · 2026-02-28

DOI: 10.1007/s11682-026-01087-0PMID: 41760984

Longitudinal Evaluation of Dysarthria Progression in Patients with Parkinson's Disease.

Vásquez-Barrientos WA, Escobar-Grisales D, Ríos-Urrego CD, Orozco-Arroyave JR.

Diagnostics (Basel) · 2026-02-26

DOI: 10.3390/diagnostics16050683PMID: 41827959

Relationship between frailty and disease progression in Parkinson's disease: a 3-year longitudinal study.

Costanzo M, Canevelli M, De Bartolo MI, Valletta M, Marchet F, Blasi MT, Leodori G, Conte A, Bruno G, Fabbrini G, Belvisi D.

Geroscience · 2026-02-24

DOI: 10.1007/s11357-026-02148-4PMID: 41731291

Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study.

Papagiannakis N, Koros C, Simitsi AM, Stefanis L, and The Parkinson's Progression Markers Initiative.

Mov Disord · 2026-02-23

DOI: 10.1002/mds.70236PMID: 41730696

Association of Statin use with Parkinson's Disease Progression in a Prospective Cohort Study and Multi-omics Analyses.

Ke L, Chen Z, Fan F, Zou X, Yi L, Zuo H, Cheng O.

J Mol Neurosci · 2026-02-21

DOI: 10.1007/s12031-026-02494-0PMID: 41721963

An explainable ensemble machine learning model using baseline blood transcriptomics to predict Parkinson's disease motor progression.

Fırat Y.

Front Digit Health · 2026-02-18

DOI: 10.3389/fdgth.2026.1774436PMID: 41789394

Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson's disease.

ASPro-PD Protokolü: Ambroksolün genetik olarak tabakalanmış Parkinson hastalığında ilerlemesini yavaşlatmak için bir faz 3 denemesi.

Toffoli M, Menozzi E, Cullen M, Chowdhury K, Ahmed S, Freemantle N, Duffen J, Wyse RK, Stott SRW, Matthews H, Dexter D, Ikeji F, Moss J, Watts P, Foltynie T, Kieburtz K, Rascol O, Poewe W, Schapira AHV.

J Neurol · 2026-02-18

DOI: 10.1007/s00415-026-13683-7PMID: 41708985

CSF LRRK2: A biomarker for slower autonomic dysfunction progression in sporadic Parkinson's disease.

Chen S, Shen Y, Shao J, Li R, Hao X, Yang H, Ma K, Zhang J.

Auton Neurosci · 2026-02-18

DOI: 10.1016/j.autneu.2026.103399PMID: 41762849

When levodopa resistance does not indicate disease progression: a case of coexisting Parkinson's disease and secondary Parkinsonism due to demyelinating lesions.

Li Y, Dai C, Nie K.

Acta Neurol Belg · 2026-02-18

DOI: 10.1007/s13760-026-03007-xPMID: 41706312